Page last updated: 2024-08-22

vidarabine and Albinism, Cutaneous

vidarabine has been researched along with Albinism, Cutaneous in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Al-Ahmari, A; Al-Dhekri, H; Al-Jefri, A; Al-Mofareh, M; Al-Mousa, H; Al-Muhsen, S; Al-Saud, B; Al-Seraihy, A; Al-Sweedan, S; Alsaedi, H; Arnaout, R; Ayas, M; El-Solh, H; Ghemlas, I; Mohammed, R; Siddiqui, K1
Behfar, M; Fazlollahi, MR; Ghavamzadeh, A; Hamidieh, AA; Hashemi, S; Moin, M; Pourpak, Z; Yari, K1

Other Studies

2 other study(ies) available for vidarabine and Albinism, Cutaneous

ArticleYear
Hematopoietic stem cell transplantation in children with Griscelli syndrome type 2: a single-center report on 35 patients.
    Bone marrow transplantation, 2020, Volume: 55, Issue:10

    Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphohistiocytosis, Hemophagocytic; Neoplasm Recurrence, Local; Piebaldism; Primary Immunodeficiency Diseases; Retrospective Studies; Transplantation Conditioning; Vidarabine

2020
Hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen in pediatric patients with Griscelli syndrome type 2.
    Pediatric transplantation, 2013, Volume: 17, Issue:5

    Topics: Child, Preschool; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immune System; Immunologic Deficiency Syndromes; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Myeloablative Agonists; Piebaldism; Primary Immunodeficiency Diseases; Prospective Studies; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2013